Estimation of further disease progression of Parkinson's disease by dopamin transporter scan vs clinical rating

Parkinsonism and Related Disorders

Volumn 17, Issue 6, 2011, Pages 459-463

  Vogt, Thomas ^a   Kramer, Katrin ^a   Gartenschlaeger, M ^a   Schreckenberger, M ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

CIT SPECT; Parkinson's disease progression

Indexed keywords

DOPAMINE TRANSPORTER; IOFLUPANE I 123; TRACER;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MALE; NEUROIMAGING; PARKINSON DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BINDING; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; AGED, 80 AND OVER; COCAINE; DISEASE PROGRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79959330847     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.04.002     Document Type: Article

References (29)

1. Brücke T., Djamshidian S., Bencsits G., Pirker W., Asenbaum S., Podreka I., et al. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 2000, 247(Suppl. 4). IV/2-7.
2. Booij J., Tissingh G., Speelmann Boer G.J., Stroof J.C., Janssen A.G.M., et al. [123] FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labeling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatr 1997, 62:133-140.
3. Benamer H.T.S., Patterson J., Wyper D.J., Hadley D.M., Macphee G.J.A., Grosset D.G. Correlation of Parkinson's disease severity and duration with [123] FP-CIT SPECT striatal uptake. Mov Disord 2000, 15:629-698.
4. Tzen K.Y., Lu C.S., Yen T.C., Wey S.P., Ting G. Differential diagnosis of Parkinson's disease and vascular Parkinsonism by (99m)Tc-TRODAT. J Nucl Med 2001 Mar, 42:408-413.
5. Seibyl J.P., Marek K.L., Quinlan D., Sheff K., Zoghbi S., Zea-Ponce Y., et al. Decreased single photon emission computed tomographic [123] ß-CIT striatal uptake correlated with symptom severity in Parkinson's disease. Ann Neurol 1995, 38:589-598.
6. Marek K., Innis R., van Dyck C., Fussel B., Early M., Eberly S., et al. [123] ß-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001, 57:2089-2094.
7. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr 1992, 55:181-184.
8. Fahn S., Elton R.L. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease 1987, Vol. 2:153-163. UPDRS Program members, Macmillan Healthcare Information, Florham Park, NJ. S. Fahn, C.D. Marsden, M. Goldstein, D.B. Calne (Eds.).
9. Guimaraes P., Kieburtz K., Goetz C.H., Elm J., Palesch Y., Hunang P., et al. Non linearity of Parkinson's disease clinical progression: implications or sample size calculations in clinical trials. Mov Disord 2005, 20(Suppl):S80.
10. Burn D.J., Rowan E.N., Allan A.M. Motor subtype and cognitive decline in Parkinson's disease. Parkinson's disease without dementia and dementia with Levy bodies. J Neurol Neurosurg Psychiatr 2006, 77:585-589.
11. Shoulsen I. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993, 328:176-183. the Parkinson Study group.
12. Winogrodzka A., Bergman P., Booij J., van Royen E.A., Janssen A.G.M., Wolters E.C. [123] FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early Parkinson's disease. J Neural Transm 2001, 108:1011-1019.
13. Goetz C.G., Stebbins G.T., Blasucci L.M. Differential progression of motor impairment in levodopa treated Parkinson's disease. Mov Disord 2000, 15:479-484.
14. Goetz C.G. What's new? Clinical progression and staging of Parkinson's disease. J Neural Transm 2006, 70(Suppl):305-308.
15. Dickson D.W., Braak H., Duda J.E., Duyckaerts C., Gasser T., Halliday G.M., et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009, 8:1150-1157.
16. Schrag A., Dodel R., Sprottke A., et al. Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord 2007, 22:938-945.
17. Maetzler W., Liepelt I., Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009, 8:1158-1171.
18. Palhagen S., Heinonen E., Hagglund J., Kaugesaar T., Mäki-Ikola O., Palm R. Selegiline slows the progression of the symptoms of Parkinson's disease. Neurology 2006, 66:1200-1206. the Swedish Parkinson Study Group.
19. Nurmi E., Ruottinen H.M., Kaasinen V., Bergman J., Haaparanta M., Solin O., et al. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand. [18F] CFT. Ann Neurol 2000, 47:804-808.
20. Pirker W., Djamshidian S., Asenbaum S., Gerschlager W., Tribl G., Hoffmann M., et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical Parkinsonism: a longitudinal ß-CIT SPECT study. Mov Disord 2001, 17:45-53.
21. Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenbach S., Jacobs A.H., et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005, 62:378-382.
22. Brück A., Aalto S., Nurmi E., Vahlberg T., Bergman J., Rinne J.O. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord 2006, 21:958-963.
23. Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson study group. Ann Neurol 1996, 40:90-107. Parkinson Study group.
24. Morrish P.K., Sawle G.V., Books D.J. An F-Dopa PET study of the rate of progression in Parkinson's disease. Brain 1996, 119:585-591.
25. Marek K., Innis R., Seibyl J. ß-CIT SPECT assessment of determinants of variability in progression of Parkinson's disease. Neurology 1999, 52(Suppl):91-92.
26. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J Neurol 2005, 252(Suppl. 4). the Parkinson Study group, IV37-IV42.
27. Oertel W.H., Wolters E., Sampaio C., Gimenez-Roldan S., Bergamasco B., Dujardin M., et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 2006, 21:343-353.
28. Jaber M., Jones S., Giros B., Caron G. The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 1997, 12:629-633.
29. Uhl G.R., Walther D., Mash D., Faucheux B., Javoy-Agid F. Dopamine transporter messenger RNA in Parkinson disease and control substantia nigra neurons. Ann Neurol 1994, 35:494-498.